Clinical Drug Investigation

, Volume 37, Issue 6, pp 581–585

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report

  • Raffaele Giusti
  • Marco Mazzotta
  • Daniela Iacono
  • Salvatore Lauro
  • Paolo Marchetti
Case Report
  • 184 Downloads

Abstract

Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is efficacious as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dosage reduction is recommended in patients with intolerable adverse events; however, data regarding the efficacy of low-dose afatinib are limited. We report the case of a 71-year-old female patient who was diagnosed with advanced EGFR-mutated NSCLC and started treatment with oral afatinib 40 mg daily. The patient achieved partial tumor response on computed tomography imaging, but developed unacceptable skin-related toxicities requiring dosage reduction to 20 mg daily. The patient subsequently achieved complete tumor response and showed improvements in performance status. These observations suggest that low-dose afatinib is effective in patients with EGFR-mutated NSCLC who require dosage reduction for intolerable adverse events.

References

  1. 1.
    Keating GM. Afatinib: a review in advanced non-small cell lung cancer. Target Oncol. 2016;11(6):825–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Boehringer Ingelheim (Canda) Ltd. Giotrif® (afatinib tablets) [product monograph]. 2016.Google Scholar
  3. 3.
    Boehringer Ingelheim Pharma Gmbh & Co. Kg. Giotrif (afatinib) film-coated tablets [summary of product characteristics]. 2016.Google Scholar
  4. 4.
    Boehringer Ingelheim Pharmaceuticals Inc. Gilotrif® (afatinib) tablets, for oral use [US prescribing information]. 2016.Google Scholar
  5. 5.
    Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  9. 9.
    Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Kumarakulasinghe NB, Van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015;20(3):370–8.CrossRefPubMedGoogle Scholar
  11. 11.
    National Comprehensive Cancer Network. Non-small cell lung cancer: NCCN clinical practice guidelines in oncology (version 3.2017). 2016.Google Scholar
  12. 12.
    Tani T, Naoki K, Asakura T, et al. Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: a case report. Mol Clin Oncol. 2016;5(4):488–90.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Hirsh V, Yang JCH, Tan EH, et al. First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). J Clin Oncol. 2016;34(Suppl):abstr 9046.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Medical Oncology UnitSant’Andrea Hospital of RomeRomeItaly

Personalised recommendations